Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct-Dec;38(4):302-309.
doi: 10.1016/j.bjhh.2016.06.004. Epub 2016 Jul 29.

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

Edvan de Queiroz Crusoe  1 , Fabiana Higashi  2 , Gracia Aparecida Martinez  3 , José Carlos Barros  2 , Marcelo Bellesso  3 , Marina Rossato  2 , Ana Cinira F Marret  2 , Carlos Sérgio Chiattone  2 , Vania Tietsch de Moraes Hungria  2
Affiliations

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

Edvan de Queiroz Crusoe et al. Rev Bras Hematol Hemoter. 2016 Oct-Dec.

Abstract

Background: Cyclophosphamide plus thalidomide as induction for multiple myeloma patients eligible for autologous stem cell transplantation may be a limiting factor for cell mobilization. The minimum acceptable mobilized peripheral blood stem cell count to prevent deleterious effects during transplantation is 2.0×106 CD34+ cells/kg. Combining other treatments to granulocyte-colony stimulating factor, such as cyclophosphamide, could overcome the mobilization limitation. The objective of this study was to assess the number of CD34+ cells mobilized using granulocyte-colony stimulating factor with and without cyclophosphamide after induction with cyclophosphamide, thalidomide and dexamethasone.

Methods: A retrospective study was performed of a cohort of multiple myeloma patients submitted to autologous stem cell transplantations at two Brazilian centers between May 2009 and July 2013. The oral cyclophosphamide and thalidomide induction doses used were 1500mg/month and 100-200mg/day, respectively. Mobilization doses were 10-15mcg/kg granulocyte-colony stimulating factor with 2-4g/m2 cyclophosphamide, or 15-20mcg/kg granulocyte-colony stimulating factor alone for 5 days. Collection of >2.0×106 CD34+ cells/kg was considered sufficient.

Results: Eighty-eight patients were analyzed; only 18 received cyclophosphamide. The median age was 58 years old (range: 51-62) for the granulocyte-colony stimulating factor group and 56.5 years old (range: 54-60) for granulocyte-colony stimulating factor plus cyclophosphamide group. Fifty-two patients were male. Eighty cases (90.9%) were Durie-Salmon Staging System III-A/B and 38 (44.7%) and 20 cases (23.5%) were International Staging System 2 and 3, respectively. The group that received cyclophosphamide collected a higher median number of progenitor cells [3.8 (range: 3.1-4.4) vs. 3.2 (range: 2.3-3.8)] (p-value=0.008). No correlation was observed between better responses or number of induction cycles and the number of cells collected.

Conclusion: The number of cells mobilized with granulocyte-colony stimulating factor plus cyclophosphamide was higher. However, in both groups, the median number of CD34+ cells was sufficient to perform a single autologous stem cell transplantation; no deleterious effects were reported during harvesting.

Keywords: Bone marrow transplantation; Cyclophosphamide; Granulocyte-colony stimulating factor; Multiple myeloma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between number of chemotherapy cycles on induction and number of CD34+ cells collected.
Figure 2
Figure 2
Progression-free survival for G-CSF and G-CSF + cyclophosphamide groups.
Figure 3
Figure 3
Overall survival for G-CSF and G-CSF + cyclophosphamide groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mohty M., Harousseau J.L. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408–416. - PMC - PubMed
    1. Auner H.W., Mazzarella L., Cook L., Szydlo R., Saltarelli F., Pavlu J. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplant. 2011;46(3):364–367. - PubMed
    1. Desikan K.R., Tricot G., Munshi N.C., Anaissie E., Spoon D., Fassas A. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112(1):242–247. - PubMed
    1. Kumar S., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Gastineau D.A. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035–2042. - PubMed
    1. Breitkreutz I., Lokhorst H.M., Raab M.S., Holt Bv, Cremer F.W., Herrmann D. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007;21(6):1294–1299. - PubMed

LinkOut - more resources